EXSCEL Cardiovascular Outcomes Study in Diabetes

This study will compare the impact of including exenatide once weekly in addition to usual care vs. usual care without exenatide on major cardiovascular outcomes as measured by the primary composite endpoint of cardiovascular-related death, nonfatal myocardial infarction (MI), or nonfatal stroke.

Awarded By

  • Amylin Pharmaceuticals

Contributors

Amount

  • $35,257,749.00

Start/End

  • 2016 - 2017